Bio-Techne Corp
NASDAQ:TECH
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
46.66
75.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ROE
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
Peer Comparison
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| US |
|
Bio-Techne Corp
NASDAQ:TECH
|
9.9B USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.2T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
223.2B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
154.9B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
81.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.3B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.3B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.3B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.2B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.6B EUR |
Loading...
|
Market Distribution
| Min | -155 749.7% |
| 30th Percentile | -2% |
| Median | 8.2% |
| 70th Percentile | 15.9% |
| Max | 143 206.7% |
Other Profitability Ratios
Bio-Techne Corp
Glance View
Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.
See Also
ROE is calculated by dividing the Net Income by the Avg Total Equity.
The current ROE for Bio-Techne Corp is 3.7%, which is below its 3-year median of 10.5%.
Over the last 3 years, Bio-Techne Corp’s ROE has decreased from 17.2% to 3.7%. During this period, it reached a low of 3.7% on Jun 30, 2025 and a high of 17.2% on Sep 30, 2022.